USPTO Art Unit 1623 Prosecution Statistics

Art Unit Information

Art Unit: 1623
Group: 1620
Tech Center: 1600
Total Cases: 12,731
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19296581METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINAugust 2025December 2025Allow400YesNo
19242489HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORSJune 2025December 2025Allow601YesNo
19213047CEVIMELINE LIQUID FORMULATIONSMay 2025December 2025Allow611YesNo
19085650BUPRENORPHINE DOSING REGIMENSMarch 2025January 2026Allow1010YesNo
19073111HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASEMarch 2025September 2025Allow701NoNo
19069899METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS VIA ADMINISTRATION OF ORGANIC TRICYCLIC COMPOUNDSMarch 2025July 2025Allow411NoNo
18996075ALCOHOL ETHER COMPOUND AND USE THEREOF IN WATER-BASED NANOPESTICIDE PREPARATIONJanuary 2025August 2025Allow701YesNo
19023371TETRAZINE COMPOUND CAPABLE OF HAVING RAPID CYCLOADDITION REACTION WITH NON-STRAINED OLEFINIC BORONIC ACID AND BIOMEDICAL APPLICATION THEREOFJanuary 2025November 2025Allow1011YesNo
19011989TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEJanuary 2025September 2025Abandon801NoNo
19000200KRAS G12D MODULATING COMPOUNDSDecember 2024May 2025Allow511YesNo
18986415Method of treating post-traumatic stress disorder with carpipramineDecember 2024March 2025Allow300YesNo
18985161METHOD OF TREATING MIDDLE EAST RESPIRATORY SYNDROME (MERS)December 2024August 2025Allow820YesNo
18961644METHODS OF TREATING INDOLENT SYSTEMIC MASTOCYTOSISNovember 2024March 2026Abandon1521YesNo
18949880METHODS AND PRODUCTS FOR IMPROVING SPERM QUALITYNovember 2024August 2025Allow911YesNo
18948449USE OF ERGOTHIONEINE TO SUPPRESS DELETERIOUS EFFECTS OF SENESCENCENovember 2024January 2026Abandon1420YesNo
18941779USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCINNovember 2024March 2025Allow401YesNo
18915070COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORSOctober 2024July 2025Allow1011YesNo
18908587COMPOSITIONS OF GRAPIPRANT AND METHODS FOR USING THE SAMEOctober 2024July 2025Allow920YesNo
18907258S-BETA-HYDROXYBUTYRIC ACID COMPOSITIONS AND METHODS FOR DELIVERY OF KETONE BODIESOctober 2024September 2025Allow1220NoNo
18852508SAFE AND STABLE NIMODIPINE FORMULATION FOR INJECTION AND METHOD FOR PREPARING SAMESeptember 2024March 2026Allow1711YesNo
18888371SOLID PSILOCIN SALTSSeptember 2024April 2025Allow711NoNo
18885140FATTY ACID COMPOSITIONSSeptember 2024April 2025Allow722YesNo
18826887PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOFSeptember 2024November 2024Allow200YesNo
18827622USE OF REBOXETINE TO TREAT NARCOLEPSYSeptember 2024November 2025Abandon1420NoNo
18824610TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITESeptember 2024September 2025Abandon1210NoNo
18813944METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF CONDITIONS CAUSED BY AN ENVELOPED VIRUSAugust 2024July 2025Abandon1120NoNo
18796446Methods for Preventing Ectopic Brain Mineralization in Alzheimer's Disease and DementiasAugust 2024November 2025Abandon1621NoNo
18778172GLUN2B-SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS WITH ENHANCED POTENCY AT ACIDIC PHJuly 2024September 2024Allow200NoNo
18763819DEUTERATED ORGANIC COMPOUNDS AND USES THEREOFJuly 2024December 2025Allow1731YesNo
18758225STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINEJune 2024July 2025Allow1320NoNo
18751006PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024October 2024Abandon410NoNo
18743333Molybdenum (0) Precursors For Deposition Of Molybdenum FilmsJune 2024September 2025Allow1511NoNo
18743944Use of Deuterated Empathogens as Therapeutic AgentsJune 2024September 2024Allow301YesNo
18741022HETEROARYL-THIO-SUBSTITUTED PYRONESJune 2024August 2025Allow1411YesNo
18718086USE OF FLIBANSERIN IN PREPARATION OF DRUG FOR TREATING ANDROGENIC ALOPECIAJune 2024November 2024Allow601YesNo
18738089(9BETA-H)-PIMARANE MOTHER NUCLEUS DITERPENOID COMPOUND WITH ANTI-COLON CANCER ACTIVITY AND DERIVATIVE THEREOF, AND PREPARATION METHOD THEREOFJune 2024October 2025Allow1610YesNo
18678198COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORSMay 2024October 2025Abandon1701NoNo
18672819COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF MITOCHONDRIAL DISEASE, INCLUDING FRIEDREICH'S ATAXIAMay 2024March 2026Abandon2211NoNo
18663502QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USESMay 2024February 2026Allow2111YesNo
18663460INHIBITING MONOACYLGLYCEROL LIPASE (MAGL)May 2024November 2024Allow610NoNo
18660695Hepatitis B Antiviral AgentsMay 2024August 2025Allow1511NoNo
18660815CD73 INHIBITORSMay 2024June 2025Allow1401NoNo
18654424MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERSMay 2024August 2025Allow1600YesNo
18654709METHOD OF TREATING MIDDLE EAST RESPIRATORY SYNDROME (MERS)May 2024December 2024Allow710YesNo
18652039GHB DOSINGMay 2024October 2025Abandon1720YesNo
18705978SHP2 AND CDK4/6 DUAL-TARGET INHIBITORY COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAMEApril 2024January 2025Allow901YesNo
18648414METHOD FOR EXTRACTING CHONDROITIN SULFATE FROM EGGSHELL MEMBRANEApril 2024June 2024Allow100NoNo
186348651-(NAPHTHALEN-2-YLOXY)-3-(PIPERIDIN-1-YL)PROPAN-2-OL AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024September 2024Allow510NoNo
18632991Acyclic Thiol ProdrugsApril 2024May 2025Abandon1301NoNo
18631828CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHODApril 2024June 2025Abandon1401NoNo
18627949CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOFApril 2024January 2026Abandon2111NoNo
18605925PROCESS FOR THE PREPARATION OF HIGH PURITY NORBORNENE SILYL ETHERSMarch 2024April 2025Allow1320YesNo
18605319REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIAMarch 2024March 2026Abandon2401NoNo
186014455-BROMO-2-HYDROXY-N'-[(1E)-1-(PYRIDIN-2-YL) ETHYLIDENE]BENZOHYDRAZIDE AS AN ANTI-CANCER AND ANTIMICROBIAL AGENTMarch 2024May 2025Abandon1420NoNo
18594323TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORSMarch 2024April 2025Abandon1310NoNo
18594233METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORSMarch 2024October 2025Abandon1920NoNo
18688333NOVEL SALT OF 2-AMINO-2-(2-(1-DECYL-1H-1,2,3-TRIAZOL-4-YL)ETHYL)PROPANE-1,3-DIOL, AND PHARMACEUTICAL COMPOSITION CONTAINING SAMEFebruary 2024May 2025Allow1420NoNo
18586477SUPERABSORBENT MATERIALS AND METHODS OF MAKING THE SAMEFebruary 2024January 2026Abandon2320NoNo
18439896METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING SALVIANOLIC ACID BFebruary 2024April 2025Allow1410NoNo
184363582,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024July 2024Allow500NoNo
18431308POTENTIATION OF HELMINTH TREATMENTFebruary 2024April 2025Abandon1410NoNo
184293507-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPYJanuary 2024July 2025Abandon1810NoNo
18428316CD73 COMPOUNDSJanuary 2024July 2025Abandon1810NoNo
18427164RAD51 INHIBITORSJanuary 2024May 2025Abandon1610NoNo
184259702-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow720NoNo
184259612-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024August 2024Allow710NoNo
18422511COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCERJanuary 2024August 2025Allow1911YesNo
18421660ANTHELMINTIC HETEROCYCLIC COMPOUNDSJanuary 2024January 2025Allow1210NoNo
18417867N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUNDJanuary 2024September 2024Allow800NoNo
18414679POLYANIONIC ACIDS TO IMPROVE RECOVERY AND MINIMIZE SYSTEM LOSSJanuary 2024March 2025Allow1401YesNo
18578864MANDELATE FORM OF 1-(4-(((6-AMINO-5-(4-PHENOXYPHENYL)PYRIMIDIN-4-YL)AMINO)METHYL)PIPERIDIN-1-YL)PROP-2-EN-1-ONEJanuary 2024March 2026Allow2600YesNo
18406539TOPICAL FORMULATIONS OF CHLOROPROCAINE AND METHODS OF USING SAMEJanuary 2024September 2025Abandon2020YesNo
18405058DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDSJanuary 2024January 2025Allow1311NoNo
18403360STERICALLY STABILIZED CARRIER COMPOSITIONS FOR TREATING A MAMMALJanuary 2024November 2024Allow1101NoNo
184025386-[4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUNDJanuary 2024October 2024Allow1030NoNo
183984804-[4,4-BIS(4-BROMOPHENYL)-5-OXO-2-THIOXOIMIDAZOLIDIN-1-YL]BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUNDDecember 2023October 2024Allow1030NoNo
18399599LYOPHYLLUM DECASTES POLYSACCHARIDE, PREPARATION METHOD AND APPLICATION THEREOFDecember 2023April 2024Allow410NoNo
18393818METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOFDecember 2023October 2024Abandon1010NoNo
18572863HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCERDecember 2023February 2026Allow2600YesNo
18393247METHODS AND COMPOSITIONS FOR IMPROVING SLEEPDecember 2023August 2025Allow2000YesNo
18540695Compositions and their Use for the Treatment of A1-Antitrypsin DeficiencyDecember 2023March 2026Allow2700NoNo
18529117SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATORDecember 2023May 2025Allow1710NoNo
18529383COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERSDecember 2023January 2026Abandon2520YesNo
18529485TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORSDecember 2023September 2025Abandon2210NoNo
18528691APPARATUS FOR TREATING BENIGN PROSTATIC HYPERPLASIADecember 2023June 2024Allow610YesNo
18522440METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINNovember 2023June 2025Allow1901NoNo
18519938COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELSNovember 2023December 2025Allow2421YesNo
18519337METHOD OF PREPARING IONIC FLUIDSNovember 2023June 2025Allow1930YesYes
18520195FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGSNovember 2023May 2024Allow610NoNo
18517380CRYSTALLINE SOLIDS OF NICOTINIC ACID MONONUCLEOTIDE AND ESTERS THEREOF AND METHODS OF MAKING AND USENovember 2023February 2024Allow300YesNo
18515734TREATING PAIN ASSOCIATED WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHYNovember 2023October 2024Allow1110NoNo
18511417USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORSNovember 2023December 2025Allow2521YesNo
18511973NUCLEOSIDE PHOSPHORAMIDATE PRODRUGSNovember 2023April 2024Allow510NoNo
18561374METHODS OF SYNTHESIS OF HETEROARYL DERIVATIVES OF TRIAZOLYL ACRYLAMIDES AND CRYSTALLINE FORMSNovember 2023March 2026Allow2800NoNo
18561308RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOFNovember 2023March 2026Allow2800NoNo
18510546BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOFNovember 2023November 2025Allow2421NoNo
18389182CHEMOKINE RECEPTOR MODULATORS AND USES THEREOFNovember 2023January 2026Abandon2620NoNo
18388765Benzimidazoles and Methods of Using SameNovember 2023November 2024Allow1210NoNo
18504672DEUTERATED COMPOUNDS AND USES THEREOFNovember 2023November 2024Allow1211NoNo
18502396STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINENovember 2023May 2024Allow710YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1623.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
163
Examiner Affirmed
118
(72.4%)
Examiner Reversed
45
(27.6%)
Reversal Percentile
24.7%
Lower than average

What This Means

With a 27.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
1196
Allowed After Appeal Filing
302
(25.3%)
Not Allowed After Appeal Filing
894
(74.7%)
Filing Benefit Percentile
17.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 25.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1623 - Prosecution Statistics Summary

Executive Summary

Art Unit 1623 is part of Group 1620 in Technology Center 1600. This art unit has examined 12,731 patent applications in our dataset, with an overall allowance rate of 58.8%. Applications typically reach final disposition in approximately 30 months.

Comparative Analysis

Art Unit 1623's allowance rate of 58.8% places it in the 13% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1623 receive an average of 1.87 office actions before reaching final disposition (in the 47% percentile). The median prosecution time is 30 months (in the 53% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.